LUCENT-3 rates at 104 weeks of continuous treatment in LUCENT-2 week 52 responders and remitters for (A) clinical response, (B) clinical remission, (C) symptomatic remission, and (D) corticosteroid-free remission, nonresponder imputation (NRI), modified NRI (mNRI), observed case. The modified intention-to-treat population was used with the NRI, mNRI, and observed case methods for missing data. Responders: ≥30% and 2-point decrease from baseline in the composite clinical endpoint of the sum of endoscopic subscore (ES) and stool frequency (SF), and rectal bleeding (RB) subscores, and RB = 0 or 1, or ≥1-point decrease from baseline. Remitters: modified Mayo score SF = 0 or SF = 1 with ≥1-point decrease from baseline; RB = 0; ES = 0 or 1. Symptomatic remission: SF = 0 or SF = 1 with ≥1-point decrease in modified Mayo score from baseline; RB = 0. Corticosteroid-free remission refers to clinical remission with no corticosteroid use for ≥12 weeks. For the mNRI method, for week 52 responders for endpoints: treatment discontinuation, 23 (9.6%); sporadic missing 32 (13.4%). For the mNRI method, for week 52 remitters: treatment discontinuation, 14 (9.1%); sporadic missing 20 (13.0%). CI, confidence interval.